This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

3,4-DAP (Jacobus)

Jacobus Pharmaceutical Company

Drug Names(s): 3,4-diaminopyridine, amifampridine

Description: The active substance of amifampridine phosphate is a potassium channel blocker which increases the release of acetylcholine and helps the muscle to receive the nerve signals. 3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

3,4-DAP (Jacobus) News

Scrip Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial

Pink Sheet Catalyst Alleges US FDA 'Facilitating' Off-Label Use With Jacobus' Ruzurgi Approval

Scrip Pipeline Watch: Phase III Starts For Linzagolix, RTB101

Pink Sheet Keeping Track: US FDA Approves Pfizer’s Vyndaqel, Jacobus’ Ruzurgi, But Nixes Acacia’s Barhemsys Again

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug